Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction chemoimmunotherapy (assessed as complete response \[CR\]/partial response \[PR\] by imaging, with EBV DNA copy number reduced to zero or below the lower limit of detection), so as to provide a new treatment option for these patients.

NCT Number	NCT07328841
Lead Sponsor	Ming-Yuan Chen
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	456 participants
Start Date	2025-11-18
Primary Completion	2030-06-30 (estimated)
Study Completion	2032-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-09